 Product DevelopmentThe company has 3 programs in place. The lead program, CVac™ has completed Phase IIa clinical trials and focuses on the development of an ex vivo immunotherapy for ovarian cancer.
>> |
|
 Scientific ResearchPrima BioMed's technologies all result from research on the human immune system. In summary, the technology platforms behind the Product Pipeline are: Dendritic cell therapy, Monoclonal Antibodies, DCtagTM adjuvant. >> |
|
 Clinical TrialCVac™ cell therapy is a new and groundbreaking technology for the treatment of cancer. It stimulates the production of immune cells, produced naturally in the body, that attack cancer cells. >> |
|
Latest News
02 February 2010
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy with a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission >>
27 January 2010
Quarterly Activity Report 31 Dec 2009 >>
22 January 2010
Matthew Lehman Appointed New Chief Operating Officer >>
Read more news >> |